key: cord-0267391-tdyvokrs authors: Charmetant, X.; ESPI, M.; Benotmane, I.; Heibel, F.; Buron, F.; Gautier-Vargas, G.; Delafosse, M.; Perrin, P.; Koenig, A.; Cognard, N.; Levi, C.; Gallais, F.; Maniere, L.; Rossolillo, P.; Soulier, E.; Pierre, F.; Ovize, A.; Morelon, E.; Defrance, T.; Fafi-Kremer, S.; Caillard, S.; Thaunat, O. title: Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection date: 2021-07-24 journal: nan DOI: 10.1101/2021.07.22.21260852 sha: 61511f75d561ec8adb0b5924ad74917111afe687 doc_id: 267391 cord_uid: tdyvokrs Transplant recipients, which receive therapeutic immunosuppression to prevent graft rejection, are characterized by high COVID-19-related mortality and defective response to vaccines. Having observed that previous infection by SARS-CoV-2 but not the standard 2 doses scheme of vaccination, provided complete protection against COVID-19 to transplant recipients, we undertook this translational study to compare the cellular and humoral immune responses of these 2 groups of patients. Neutralizing anti-Receptor Binding Domain (RBD) IgG were identified as the critical immune effectors associated with protection. Generation of anti-RBD IgG was dependent upon spike-specific T follicular helper (Tfh) CD4+ T cells, which acted as limiting checkpoint. Tfh generation was impeded by high dose mycophenolate mofetil in non-responders to vaccine but not in infected patients, suggesting that increasing immunogenicity of vaccine could improve response rate to mRNA vaccine. This theory was validated in two independent prospective cohorts, in which administration of a 3rd dose of vaccine resulted in the generation of anti-RBD IgG in half of non-responders to 2 doses. In December 2019, an outbreak of apparently viral pneumonia of unknown etiology emerged in the city of Wuhan, in the Chinese province of Hubei (1). On 9 January 2020, the World Health Organization (WHO) announced the discovery of a novel coronavirus officially named SARS-CoV-2, which is the pathogen responsible for this infectious respiratory disease called COVID-19 (CoronaVIrus Disease). The disease quickly disseminated from Wuhan and as at 8 July 2021, more than 184 million cases have been confirmed in 214 countries (2) , leading the WHO to consider COVID-19 as the first pandemic triggered by a coronavirus. Among the various alarms raised by the pandemic was its impact on the population of transplanted patients, whose COVID-19-related mortality was estimated 20%, several magnitudes higher than that of the general population (3) (4) (5) (6) (7) . This vulnerable population of patients was therefore prioritized for vaccination against SARS-CoV-2 by health authorities (8). However, prevention of allograft rejection requires life-long immunosuppression regimens, which non-specifically inhibit T and B cells in transplant recipients, resulting in reduced response rates to vaccines (9, 10). As expected, several recent publications have documented that immunosuppressed transplant recipients develop mitigated immune responses following the "standard" 2 doses scheme of vaccination with any of the 2 approved SARS-CoV-2 mRNA vaccines (11) (12) (13) (14) . Although insufficiency of vaccinal protection in transplant recipients has emerged as a concern due to accumulating reports of severe COVID-19 in vaccinated patients (15, 16) , the underlying immune mechanisms explaining this problem are still elusive (17) . In an attempt to determine the relative contribution of humoral and T cell immunity in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07. 22 .21260852 doi: medRxiv preprint 5 conferring protection against COVID-19 and understand immunosuppression-induced defects following SARS-CoV-2 vaccination, we undertook a prospective translational study that compared infected and vaccinated transplant recipients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07. 22 .21260852 doi: medRxiv preprint The incidence of COVID-19 was monitored in all 889 renal transplant recipients of Strasbourg University Hospital and compared between those with previous history of infection with SARS-CoV-2 (group "infected", n=153) and those who received the 2 doses "standard" scheme of vaccination with mRNA-1273 (group "vaccinated", n=736; Figure 1A ). Strikingly, while none of the infected patients did develop reinfection, 15 vaccinated patients (0% vs 2.04%, p=0.037) developed COVID-19 ( Figure 1B) . Of note this observation was made while the follow-up period of infected patients was significantly longer than that of vaccinated patients (243+/-161 vs 102+/-18 days, p<0.0001; Figure 1A ). We concluded that in contrast with vaccination, SARS-CoV-2 infection confers full protection against COVID-19 to immunocompromised transplant recipients. Comparison of cellular and humoral immune responses developed by infected and vaccinated transplant patients offers a unique opportunity to determine which immune effector(s) are associated with protection against COVID-19 in this vulnerable population (3-7). The COVATRHUS cohort was therefore established to prospectively collect synchronous serum and PBMCs samples from renal transplant recipients diagnosed with COVID-19 in absence of previous vaccine injection (group "infected", n=21) or vaccinated with 2 doses of mRNA-1273 (group "vaccinated", n=29). The clinical All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint 7 characteristics of the cohort are presented Table 1 . Briefly, the 2 groups had similar profiles, except for lymphocytes and monocytes counts that were lower in infected patients ( Table 1) . Of note, the severity of COVID-19 in infected patients was mainly mild/moderate (16/21, 76%; Table 2 ) and most of them did not require hospitalization (14/21, 67%; Table 2 ). Virus-specific CD8+ T cells reduce disease severity and promote recovery in many respiratory infections, including those driven by coronaviruses (23, 24) , by eliminating infected cells (virus "factories"). Optimal generation of these cytotoxic effectors depends upon the help provided by the Th1 CD4+ T cells (25). Cytotoxic CD8+ T cells directed against the spike protein of SARS-CoV-2, identified by the co-expression of CD69 and CD137 (20) , could be detected in the circulation of both vaccinated and infected patients (Figure 2A) . However, only the latter had CD8+ T cells directed against the other proteins of the virus (nucleocapsid and membrane). This finding was expected since nucleocapsid and membrane proteins are not included in the vaccine formulation (Figure 2A & 2B) . Despite a trend for more spike-specific CD8+ T cells in the circulation of infected patients, the difference with the vaccinated group did not reach statistical significance ( Figure 2B) , even when all specificities (spike, nucleocapsid and membrane) were added together to better take into account the difference of repertoire size between the 2 groups ( Figure 2C ). The exact same observations were made when the analysis was focused on Th1 subset of CD4+ T cells (Figure 2D-F) . We concluded that although the repertoire of the cellular immune response directed against SARS-CoV-2 is wider in infected patients (Figure 2G) , the resulting small (and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint 8 non-significant) increase in cellular effectors is unlikely to account alone for the drastic advantage in term of protection observed as compared with vaccinated transplant recipients (Figure 1 ). Another strong argument in favor of this hypothesis is the fact that some infected patients ( Figure 2G ) had no detectable virus-specific T cells, suggesting that their protection was due to other types of immune effectors. Beside cellular effectors, the adaptive immune system also generates antibodies against SARS-CoV-2. As expected, antibodies directed against viral nucleocapsid (not included in the vaccine formulation) were exclusively detected in patients from the infected group In striking contrast with infected patients, the humoral response of the vaccinated group against RBD was heterogeneous, since most patients (17/29, 59%) failed to generate detectable levels of anti-RBD IgG after 2 doses of vaccine ( Figure 3B ). This defect All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint was even more patent when considering the functional assay, in which only 21% of vaccinated patients had neutralizing humoral response against the pseudovirus (6/29; Figure 3C ). These findings led us to hypothesize that the lack of protection against COVID-19 in some vaccinated transplant recipients may be due to insufficient generation of neutralizing anti-RBD antibodies. To test this theory, we retrieved the 14 available serum samples collected after the 2 doses of mRNA-1273 but prior COVID-19 diagnosis for the vaccinated patients of the first cohort. In line with our theory, almost all these patients (12/14, 86%; Figure 3E ) had no anti-RBD IgG after the "standard" scheme of vaccination and, consequently, their serum was unable to block the entry of pseudo-virus in human cells in neutralization assay ( Figure 3E ). The generation of IgGs against a protein antigen (such as spike) depends upon a prototypical T-cell-dependent humoral response. Following the binding of the antigen to their surface immunoglobulin (which delivers the first signal of activation), spikespecific B cell clones indeed require a second signal of activation that comes from cognate interactions with CD4+ T follicular helper (Tfh) cells (32) (33) (34) . Because our group (9, 32) and others (35) have shown that maintenance immunosuppression heterogeneously impacts Tfh population in transplant recipients, we speculated that a Tfh defect could explain the lack of generation of neutralizing antibodies observed in some vaccinated patients. To test this theory, the 29 vaccinated transplant recipients were distributed into the group "responder" (n=12/29, 41%) or "non-responder" (n=17/29, 59%) according to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint whether or not they had detectable level of anti-RBD IgG in their circulation after 2 doses of mRNA-1273 vaccine. Clinical and biological characteristics of these two groups are presented in Table 3 and were similar, except for age that was lower in the patients of the "responder" group. Although Tfh cells act in B cell area within secondary lymphoid organs, recent studies have demonstrated that human blood CXCR5 + CD4 + T cells are counterparts of Tfh and contain specific subsets that differentially support antibody secretion and can be identified on the basis of their profile of chemokine receptor expression (36) . In line with these previous works, the 3 subsets of Tfh: Tfh1 (CXCR3 + CCR6 -), Tfh2 (CXCR3 -CCR6 -), Tfh17 (CCR6 + ), could be identified and enumerated by flow cytometry in the circulation of vaccinated patients ( Figure 4A) . No difference was observed regarding the global count of CD4+ T cells, Tfh, or any of the Tfh subsets between responders and non-responders ( Figure 4B ). However, in line with our theory, spike-specific Tfh 1 and Tfh17 clones, which are the most efficient to drive antibody generation (9, 36), were found in higher quantity in the circulation of responders than non-responders (Tfh1: 30334570 vs 664859 cells/mL, p=0.024; and Tfh17: 10101269 vs 306385 cells/mL, p=0.020 in responders vs non responders; Figure 4C ). Basic immunology works have demonstrated that Tfh number is a major limiting checkpoint that regulates the dynamic of germinal center reaction (37, 38) . The reduced count in spike-specific Tfh therefore provides a likely explanation to the lack of generation of anti-RBD IgG in non-responders to vaccine. What could be the reason for this problem? Among the immunosuppressive drugs used in maintenance regimen, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint some block the activation of T cells (calcineurin-inhibitor) while other act by blocking the proliferation of adaptive immune effectors (mycophenolate mofetil). While responders and non-responders to vaccine were similarly exposed to calcineurininhibitors, non-responders received significantly more mycophenolate mofetil (500mg/day, IQR [0,1000] vs 1000mg/day, IQR [500; 1000] in responders vs non responders, p=0.027; Figure 5A ). Our last observation led us hypothesizing that the detrimental impact of high dose mycophenolate mofetil could be overcome by a stronger/more immunogenic stimulation than the vaccine, such as the one provided to the patients by infection with live virus. In line with this hypothesis, vaccinated patients without anti-RBD IgG after 2 doses of mRNA-1273 did generate anti-RBD IgG after infection ( Figure 6A ). Based on these results, we went on testing the impact of an additional dose of vaccine on the anti-RBD IgG response of 13 of the 17 transplant patients that were nonresponders to the "standard" 2 doses scheme of vaccination with mRNA-1273. In All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint 12 accordance with our hypothesis, we observed that 7/13 (54%) did develop anti-RBD IgG after the 3 rd dose of vaccine ( Figure 6B ). Aiming at validating this finding in an external cohort, a 3 rd dose of BNT162b2 mRNA vaccine was injected to a cohort of 36 renal transplant recipients from Lyon University hospital without detectable anti-RBD IgG after 2 injections. In accordance with our previous results, about half (15/36, 42%; Figure 6C ) of these non-responders developed anti-RBD IgG after the 3 rd dose of vaccine. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. While antibody levels are emerging as correlates of protection against COVID-19 in healthy subjects (39) , there is still an urgent need to understand the relative contribution of humoral and T cell immunity in conferring protection to immunosuppressed populations (17) , in particular transplant patients, who are both at high risk of death due to COVID-19 (3-7) and poor responders to mRNA vaccines (11) (12) (13) (14) . Taking advantage of an original observation: i.e., that a previous infection by SARS-CoV-2 but not the standard "2 doses" scheme of vaccination, provided protection against COVID-19 to transplant recipients, we designed this translational study to compare the adaptive immune responses of these 2 groups of patients. This approach identified the generation of anti-RBD-IgG as a critical component of the adaptive immune response associated with protection against COVID-19 in transplant recipients. Generation of switched (IgG) antibodies against a protein antigen depends upon the germinal center, which is known to be controlled by Tfh cells, a subset of CD4+ T cells that act as the major limiting checkpoint of this reaction (37, 38) . In line with these basic immunology works, non-responders to SARS-CoV-2 mRNA vaccine (i.e. transplant patients without anti-RBD-IgG after 2 doses of vaccine) were indeed characterized by reduced numbers of spike-specific Tfh cells. This was likely due to higher exposure to mycophenolate mofetil, an immunosuppressive drug that act by blocking the proliferation of activated lymphocytes (40, 41) . This theory is supported by other independent studies, which have also observed an association between exposition to mycophenolate mofetil and lower antibody responses (35, 42, 43) , including to SARS-CoV-2 vaccines (11, 14) . Based on these findings, it is tempting to speculate that a reduction (or suspension) of the maintenance dose of mycophenolate All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint mofetil prior vaccination might help obtaining better response rates. On the other hand, this non-antigen specific attitude might also favor the expansion of donor-specific Tfh, and therefore increase the risk of generation of de novo donor-specific antibodies (9), which is the first cause of late allograft loss (44) through accelerated chronic vascular rejection (45, 46) . (47, 48) . In addition to increasing the number of injections, another possibility to increase vaccine immunogenicity is to increase the amount of antigen provided in each injection. This strategy has been successfully tested in transplant recipients with protein-based vaccines against influenza (49, 50). However, it is unclear whether (and to which extend) increasing the doses of mRNA would result in an increased production of the pathogen-derived protein antigen by patient's cells with these new vaccines platforms. To the best of our knowledge, there is currently no data in the literature addressing this issue. At last, adaptation of vaccination scheme has limits and there will probably remain a fraction of transplanted patients that cannot generate an efficient antibody response whatever the vaccination scheme. In the latter, protection against COVID-19 might All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The incidence of SARS-CoV-2 infections was monitored since the beginning of the pandemic, in the entire cohort of kidney transplant recipients at the University Hospital of Strasbourg (France), and compared between patients with a previous history of COVID-19 and those who received the 2 doses "standard" scheme of vaccination with mRNA-1273. The protection conferred by mRNA vaccine is operant as early as 12 days after the first injection in the general population (18) . Transplant recipients were therefore considered "vaccinated" if they had received the second dose of vaccine. Kaplan-Meier's method was used to compare COVID-19 incidence in the 2 populations. Data were censored at either date of death or June 16, 2021. To analyze the immune mechanisms involved in protection against COVID-19, 29 patients, naive for SARS-CoV-2 infection, were prospectively recruited from the cohort of kidney transplant recipients of the University Hospital of Strasbourg (France). According to the recommendations of the French health authority, they received a standard (2 doses) vaccination with mRNA-1273 (Moderna) COVID-19 vaccine. A third vaccine injection of mRNA-1273 COVID-19 vaccine was offered to all patients who did not develop IgG against the receptor binding domain of spike viral protein (anti-RBD IgG) after the second dose. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. Peripheral Blood Mononuclear Cells (PBMC) were collected and isolated by centrifugation on a Ficoll density gradient. The cells were then frozen in fetal calf serum supplemented with 10% dimethylsulfoxide (DMSO, Sigma). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The SARS-CoV-2 specific CD8+ T cells and CD4+ T cells were identified as previously described (9, 20) . Briefly, after thawing, cells were concentrated at 10^7 cells/mL in RPMI complete medium and left to rest overnight at 37°C and 5% CO2 in a 96-well round-bottom plate, 10^6 cells/well. The next day, the RPMI medium was changed, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Following WHO recommendation (21) , the titers are expressed as binding antibody units/mL (BAU/mL); correction factor for Maglumi®: 4.33. The Abbott anti-N IgG assay is an automated chemiluminescence microparticle immunoassay (CMIA) conducted and interpreted according to manufacturer guidelines. A sample-to-calibrator relative light unit index of ≥1.4 is considered positive, an index of ≥0.49 to <1.40 is considered borderline, and an index of <0.49 is considered negative. This CMIA displays clinical sensitivity and specificity of 96.5% and 99.2%, respectively (22) . The assay was performed as follows: All the analyses were carried out using GraphPad Prism v8.0 (San Diego, California USA). Qualitative variables were expressed as percentages and compared with the chi-squared test, or Fisher's exact test when the conditions of application of chi-square were not respected. Quantitative variables were expressed as mean ± SD and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint 20 compared using multiple t-tests or as median ± IQR and compared using Mann-Whitney test for variables with non-normal distribution. Paired data were compared using Wilcoxon test. Incidence data analyzed by the Kaplan-Meier's method were compared using a Log-rank test. A non-linear regression was performed to study the correlation of continuous quantitative variables. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint Protection against COVID-19 was compared between renal transplant recipients with previous history of infection with SARS-CoV-2 (group "infected", grey curve) and those who received the 2 doses "standard" scheme of vaccination with mRNA-1273 (group "vaccinated", black curve). A. Cumulative incidence in the two groups was plotted using the Kaplan-Meier method. Log-rank test, p=0.06. B. Percentage of patients who developed COVID-19 in the 2 groups was compared. Chi-square test, *: p0.05. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Median are shown. Multiple t-tests, p>0.05. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wilcoxon test; ***, p<0.001, ****, p<0.0001. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (97) 22 (76) 19 (66) 3 (10) 1 (3) 19 (90) 20 (95) 14 (67) 1 (5) 1 ( All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint Table 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint China Novel Coronavirus Investigating and Research Team, A Novel Coronavirus from Patients with Pneumonia in China COVID-19 situation update worldwide, as of week 26 Factors associated with COVID-19-related death using OpenSAFELY An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe French nationwide Registry of Solid Organ Transplant Recipients with COVID-19, IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients Circulating Tfh17 Predicts Humoral Response to Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine French Society of Transplantation, Occurrence of severe COVID-19 in vaccinated transplant patients Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Targets of T Cell Responses to SARS-CoV Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results T-cell quality in memory and protection: implications for vaccine design Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation Human neutralizing antibodies elicited by SARS-CoV-2 infection The ROMANOV study found impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression. Front Immunol Antigen-specific interaction between T and B cells Follicular helper CD4 T cells (TFH) Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center B Cell Competition for Restricted T Cell Help Suppresses Rare-Epitope Responses Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure Recent advances in renal transplantation: antibody-mediated rejection takes center stage. F1000Prime Rep Humoral immunity in chronic allograft rejection: Puzzle pieces come together Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial BLAZE-2 Investigators Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial The authors are indebted to Audrey Kochman and the members of the GRoupe de All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint 31 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Authors declare that they have no competing interests.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint patient. Sunburst charts were used to compare non-responders (left) and responders (right). Multiple t-tests; *, p<0.05. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.22.21260852 doi: medRxiv preprint